SCHEMBL4897616

SCHEMBL4897616

CCn1nc(-c2ccccc2)c(C(C)=O)c(Nc2cc(C(N)=O)ccc2C)c1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 4/20 0.66
TP53 P04637 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.41
CSF1R P07333 1/20 0.41
FGFR1 P11362 1/20 0.41
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
CSNK1A1 P48729 1/20 0.41
CDK8 P49336 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
CDK5 Q00535 1/20 0.41
PRKCQ Q04759 1/20 0.41
LRRK2 Q5S007 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
LMNA P02545 1/20 0.41
CAMKK2 Q96RR4 1/20 0.40
LCK P06239 1/20 0.40
MAPK14 Q16539 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707588 0.91 PDE4B (0.64) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4707781 0.89 PDE4B (0.62) PDE4BTP53CAMKK2
SCHEMBL4708504 0.88 PDE4B (0.65) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4705603 0.87 PDE4B (0.69) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4707916 0.86 PDE4B (0.63) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4707184 0.86 PDE4B (0.63) PDE4BTP53SMN1; SMN2LMNA
SCHEMBL4708446 0.86 PDE4B (0.84) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4707707 0.85 PDE4B (0.73) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4706065 0.85 PDE4B (0.70) PDE4BTP53SMN1; SMN2CSF1RFGFR1
SCHEMBL4708527 0.84 PDE4B (0.65) PDE4BTP53SMN1; SMN2CSF1RFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
EP-1503992-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2005-02-09 EP disclosed
WO-2003097613-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE4 INHIBITORS ALMIRALL PRODESFARMA SA (ES) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885TP53 4836/4885SMN1; SMN2 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.